LAS VEGAS, NV--(Marketwired - Oct 7, 2015) - Alkame Holdings, Inc. (
Each of the Athletic Lab team members bring expertise in their respective field, and are widely recognized for their contributions to sports and movement science research using science-based, field-proven methods. Athletic Lab's services have been used by the U.S., Chinese & South African Olympic teams as well as pros from the MLS, NFL, and MLB & PGA.
The studies were conducted under the supervision of Mike Young PhD, recognized Certified Strength & Conditioning Specialist (CSCS) from the National Strength & Conditioning Association, a Level 3 coach by USA Track & Field, a Level 2 coach by USA Weightlifting, and a Cross Fit Level 1 coach. He is on the advisory board for the Korean Weightlifting Federation, and has served as an instructor or professor at Louisiana State University (LSU), University North Carolina (UNC) & Ohio University. Additionally, he is a lead instructor for coaching education programs from USA Track & Field (USATF), U.S. Track & Field and Cross Country Coaches Association (USTFCCCA) & USA Weightlifting. Young has also been featured in publications including the New York Times and ESPN Insider, and has authored or co-authored research on sprinting, balance, motor learning, stretching & biomechanics of throwing that has been published in peer-reviewed international research journals.
The study was conducted using healthy athletic individuals ages 20-42. Basic individual measurements (age, height, weight, resting heart rate) were collected on each participant. Each individual participated in the exercise protocol; that protocol was 8x100m sprints on 1 minute intervals with a standardized completion time. Blood lactate was taken before and after the conclusion of the sprints using a Lactate Plus monitor from Nova Biomedical.
The first week of the study was a control week in which each participant consumed 3L of tap water per day prior to a standardized warm up and exercise protocol. Data was collected during this time as a base measurement.
After the control week, subjects were split into two equal groups and provided unmarked bottles of water. Group 1 received bottled tap water and group 2 received Alkame Water. Each participant was instructed to consume 3L of the bottled water prior to a standardized warm up and the exercise protocol. Results of a T-test indicated that both groups improved their lactate response to the exercise protocol. However group 2 that received the Alkame Water did in fact improve to a significantly greater extent.
Overseeing the study was Dr. Pietro Baio and Tammy Miller, who stated, "The study conducted by Mike Young and the Athletic Lab definitely provided scientific evidence that Alkame Water lowers lactic acid accumulation during repetitive sprints/interval training. They continued, "This means that drinking Alkame Water prior to and during workouts will help reduce muscle soreness, allowing for less fatigue, longer workouts, and faster muscle recovery."
About Alkame Holdings, Inc. (ALKM)
Alkame Holdings, Inc. is a publicly traded health and technology holding company with a focus on patentable, innovative, and eco-friendly consumer products. The Company's wholly-owned subsidiary, Alkame Water, Inc., markets and distributes micro-clustered, alkaline, antioxidant and oxygenated bottled water utilizing an exclusive patented formula and technology. Alkame uses this patented technology to create water with several unique properties which allow the body to absorb and utilize it more efficiently and help to achieve an optimal pH balance. This patented technology also increases the available oxygen content and absorbability which equates to more fuel for improved metabolic efficiency, boosted immune system, and improved cardio respiratory function.
For more information visit: www.alkameholdingsinc.com
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that Alkame will achieve significant sales, the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.